MEDIA

Latest News

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences.

19 August 2020

Novel botulinum toxin type A earns high marks for forehead lines

04 August 2020

Revance Reports Positive Results in Two Phase 2a Studies of DAXI

29 July 2020

Dustin S. Sjuts of Revance Therapeutics: Five Things You Need To Know To Succeed In The Modern Beauty Industry

27 July 2020

DaxibotulinumtoxinA Aims to Be Next Big Post-Stroke Spasticity Treatment

23 July 2020

Bloomberg: Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices

07 July 2020

Modern Aesthetics: Revance’s DaxibotulinumtoxinA for Injection Looks Good in Phase 2 Studies of Forehead Lines and Crow’s Feet

07 July 2020

Data Shows Six Month Duration for Revance DaxibotulinumtoxinA

08 April 2020

Peter McAllister, MD: JUNIPER Trial on DaxibotulinumtoxinA for Spasticity

18 June 2019

MEDIA

Latest News

Novel botulinum toxin type A earns high marks for forehead lines

Revance Reports Positive Results in Two Phase 2a Studies of DAXI

Dustin S. Sjuts of Revance Therapeutics: Five Things You Need To Know To Succeed In The Modern Beauty Industry

DaxibotulinumtoxinA Aims to Be Next Big Post-Stroke Spasticity Treatment

Bloomberg: Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices

Modern Aesthetics: Revance’s DaxibotulinumtoxinA for Injection Looks Good in Phase 2 Studies of Forehead Lines and Crow’s Feet

Data Shows Six Month Duration for Revance DaxibotulinumtoxinA

Peter McAllister, MD: JUNIPER Trial on DaxibotulinumtoxinA for Spasticity

Thrive Global: Dustin S. Sjuts of Revance Therapeutics: Why A Leader Should Create Space for Debate